Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.17% is 46% below its 5-year average of -26.14%, around the middle of its 5-year range (-56.15%–-17.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.41% below its 12-month average of -31.44%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.17%.
RETURN ON EQUITY (ROE)
-38.17%
RETURN ON EQUITY (ROE) AVG TTM
-31.44%
RETURN ON EQUITY (ROE) AVG 3Y
-25.18%
RETURN ON EQUITY (ROE) AVG 5Y
-26.14%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.41%
CURRENT VS 3Y AVG
-51.59%
CURRENT VS 5Y AVG
-46.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.54%
median of 579 covered companies
CURRENT VS SECTOR MEDIAN
+3.46%
vs the sector median at left
Disc Medicine, Inc.
Market Cap
$2.46B
Return on Equity (ROE)
-38.17%
TTM Avg
-31.44%
3Y Avg
-25.18%
5Y Avg
-26.14%
Market Cap
$2.44B
Return on Equity (ROE)
-56.71%
TTM Avg
-50.91%
3Y Avg
-55.48%
5Y Avg
-35.68%
Market Cap
$2.43B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.42B
Return on Equity (ROE)
-4.88%
TTM Avg
-20.16%
3Y Avg
-52.49%
5Y Avg
-49.61%
Market Cap
$2.39B
Return on Equity (ROE)
41.39%
TTM Avg
43.71%
3Y Avg
5.79%
5Y Avg
-18.90%
Market Cap
$2.38B
Return on Equity (ROE)
-84.78%
TTM Avg
-42.91%
3Y Avg
-54.25%
5Y Avg
-44.36%
Market Cap
$2.37B
Return on Equity (ROE)
71.04%
TTM Avg
-161.38%
3Y Avg
-133.53%
5Y Avg
-111.86%
Market Cap
$2.32B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.31B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.46B | -38.17% | -31.44% | -25.18% | -26.14% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.44B | -56.71% | -50.91% | -55.48% | -35.68% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.43B | N/A | 9.38% | 9.38% | 9.38% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.42B | -4.88% | -20.16% | -52.49% | -49.61% |
| ADMA Biologics, Inc. (ADMA)vs › | $2.39B | 41.39% | 43.71% | 5.79% | -18.90% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.38B | -84.78% | -42.91% | -54.25% | -44.36% |
| Liquidia Corporation (LQDA)vs › | $2.37B | 71.04% | -161.38% | -133.53% | -111.86% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.32B | 18.14% | 20.16% | 28.24% | 15.58% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.31B | -37.82% | -53.05% | -23.57% | 8.38% |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.63B | -41.10% | -30.86% | -32.08% | -34.60% |
ROE
-38.2%
ROA
-33.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.17% |
| 2026-03-31 | -35.09% |
| 2025-12-31 | -28.68% |
| 2025-09-30 | -31.59% |
| 2025-06-30 | -23.67% |
| 2025-03-31 | -17.64% |
| 2024-12-31 | -24.65% |
| 2024-09-30 | -22.11% |
| 2024-06-30 | -18.62% |
| 2024-03-31 | -23.84% |
| 2023-12-31 | -22.15% |
| 2023-09-30 | -20.64% |
| 2023-06-30 | -20.50% |
| 2023-03-31 | -29.95% |
| 2022-12-31 | -32.17% |
| 2022-09-30 | -51.07% |
| 2022-06-30 | -52.21% |
| 2022-03-31 | -56.15% |
| 2021-09-30 | -31.84% |
| 2021-06-30 | -23.03% |
| 2021-03-31 | -15.56% |
